profit from every $100 of sales.
$0$100
GSK
$50.45-0.38% today
+4.8% in 1 year
1-year low $46.111-year high $61.18
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $13.39 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What GSK sold, what it kept, and what it did with the cash.
Sales went from £29.3 billion in 2022 to £32.7 billion in 2025, with £5.72 billion of profit last year.
SalesProfit
GSK handed back 83% of the cash it generated last year.
Buybacks £1.4B£2.6B
Free cash flow 2025£4.8B
Bought back its own shares£1.4B
Paid as dividends£2.6B
Cash vs. debt£3.2B vs. £17.7B
GSK vs. similar companies
GSK grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| GSK | 13.4× · Cheap | ||
 Eli Lilly | 62.3× · Very expensive | ||
 Johnson & Johnson | 25.7× · Fair price | ||
 AbbVie | 123.4× · Very expensive | ||
 Roche | 25.5× · Fair price |
Compare GSK with AbbVie · Johnson & Johnson · Eli Lilly · Roche · UnitedHealth
AI analysis
An AI analyst reads GSK's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 29,324 | 30,328 | 31,376 | 32,667 | |
| 19,770 | 21,763 | 22,328 | 23,650 | |
| 6,729 | 7,345 | 5,542 | 8,338 | |
| 8,601 | 9,083 | 6,668 | 10,402 | |
| 14,956 | 4,928 | 2,575 | 5,716 | |
| 7.32 | 2.40 | 1.24 | 2.78 | |
| 67.4% | 71.8% | 71.2% | 72.4% | |
| 22.9% | 24.2% | 17.7% | 25.5% | |
| 51.0% | 16.2% | 8.2% | 17.5% |
Balance sheet
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 60,146 | 59,005 | 59,463 | 61,118 |
| Cash | 3,523 | 2,746 | 3,693 | 3,150 |
| Total debt | 20,987 | 18,018 | 16,986 | 17,720 |
| Total liabilities | 50,050 | 46,210 | 46,377 | 45,162 |
| 10,598 | 13,347 | 13,671 | 16,377 | |
| 2,042 | 2,056 | 2,071 | 2,059 | |
| 16.1% | 17.1% | 10.6% | 18.7% | |
| 141.1% | 36.9% | 18.8% | 34.9% |
Cash flow
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 7,403 | 6,768 | 6,554 | 7,741 | |
| 2,258 | 2,344 | 2,982 | 2,985 | |
| 5,145 | 4,424 | 3,572 | 4,756 | |
| Dividends paid | 3,467 | 2,247 | 2,444 | 2,564 |
| – | 0 | 0 | 1,377 | |
| 346 | 307 | 344 | 374 |
Valuation
- 13.4×
- 10.4×
- –
- 4.5×
- 2.3×
- 16.1×
- 8.8×
- 6.2%
- 7.5%
- 3.3%
Profitability
- 72.4%
- 25.5%
- 17.5%
- 35.3%
- 19.2%
- 16.0%
- 35.8%
- 9.3%
- 18.1%
- 23.5%
Growth
- +3.7%
- −27.6%
- +63.1%
- −3.8%
- +0.3%
Financial health
- 1.4×
- 1.08
- 30.3%
- 11.8×
- 0.82
- 0.52
- 0.52
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 10%of 963
Top 15%of 894
Top 18%of 632
Bottom 25%of 908
Top 17%of 991
What analysts expect
- Average price target
- $52.45
- Range
- $35.25 – $85.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | 1.24 | 1.16 | +6.9% |
| Feb 4, 2026 | 0.68 | 0.64 | +6.3% |
| Oct 29, 2025 | 1.48 | 1.26 | +17.5% |
| Jul 30, 2025 | 0.96 | – | – |
| Apr 30, 2025 | 1.13 | 1.08 | +4.6% |
| Feb 5, 2025 | 0.59 | 0.44 | +34.1% |
| Oct 30, 2024 | 1.27 | 1.16 | +9.5% |
| Jul 31, 2024 | 1.09 | 1.00 | +9.0% |
3.3%of the share price, paid each year
On $1,000 invested$33a year at today's yield, before tax
−3.8%2020 to 2025
Raised2 yearsin a row, in our data
Paid per share, each year
$2.45 in 2015 → $1.70 in 2025
How safe it looks
44.9% of its profit
Room to growStretchedMore than it earns: 53.9%
News
GSK declares $0.4524/ADS or 17p/share dividendSeeking Alpha · Oct 28, 2026AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilotSeeking Alpha · Oct 3, 2026GSK Gets a Lung Cancer PayoffYahoo Finance · Sep 14, 2026GSK's Jemperli gets FDA priority review for rectal cancerSeeking Alpha · Aug 24, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
62Pass
Benjamin Graham
54No pass
Philip Fisher
64Pass
Peter Lynch
31No pass
Joel Greenblatt
57No pass
Charlie Munger
68Pass
Terry Smith
60Pass
Questions about GSK
Is GSK a good stock to buy?
A solid business, and the price looks low. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the GSK AI analysis
What does GSK do?
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It is in Drug Manufacturers - General, based in London, United Kingdom, with 66,841 employees.
Does GSK pay a dividend?
Yes. At today's price the dividend is 3.3% a year, about 45% of its yearly profit. In 2025 it paid out $2.56 billion in dividends.
Is GSK stock halal?
Yes. GSK passes our halal screen: its business is permitted and its debt is 23% of its market value, under the 30% limit. How we check
How has GSK stock done over the past year?
Up 4.8% over the past twelve months, to $50.45. It traded between $46.11 and $61.18 and is 17.5% below its high.
Who are GSK's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with GSK's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.